Analyst Lee Hambright from Bernstein maintained a Buy rating on Insulet (PODD – Research Report) and increased the price target to $335.00 from $315.00.
Lee Hambright’s rating is based on Insulet’s strong performance in the fourth quarter of 2024 and its promising outlook for 2025. The company demonstrated robust revenue growth, particularly with its Omnipod product, which saw significant increases in both the U.S. and international markets. This growth was bolstered by new product integrations and launches, such as the G7 integration and the Omnipod 5 release in several new countries.
Additionally, Insulet’s impressive gross and operating margins exceeded market expectations, highlighting improved efficiencies and favorable pricing strategies. The conservative guidance for future growth, combined with a price target increase to $335, reflects confidence in the company’s potential for continued success, driven by execution in type 2 diabetes solutions and margin expansion. The stock’s current trading multiple is considered attractive relative to historical averages, suggesting further upside potential.
According to TipRanks, Hambright is a 4-star analyst with an average return of 12.8% and a 79.31% success rate. Hambright covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Edwards Lifesciences, and Abbott Laboratories.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $324.00 price target.